American biotech urgently needs a coordinated plan to beat China

By John F. Crowley

China just announced a new five-year plan that designates biotechnology as a national "pillar industry" and aims to displace the United States as the world's biotech leader. Those ambitions threaten one of America's defining competitive advantages -- and they demand an urgent response.

America's biotech sector supports nearly 10 million jobs and over $3 trillion in annual economic activity. It fuels advanced manufacturing growth, ensures our loved ones have access to the newest and most groundbreaking medicines, and strengthens our defenses against pandemics and biological threats.

Yet biotech innovation also depends on numerous interconnected players -- from the university laboratories and startups that often pioneer new research to the trial networks and manufacturing facilities that bring medicines to patients. That means there's no single policy that will protect our lead. Instead, we need a plan that strengthens every facet of our biotech ecosystem.

Today’s biotech race is our generation’s Space Race. A new action plan from the Biotechnology Innovation Organization outlines how America can marshal its resources, strengthen its scientific leadership, and prevail in the global competition for biotechnology leadership.

That effort requires greater coordination in Washington.

In other strategic sectors, such as artificial intelligence and quantum technology, federal leaders have established dedicated offices to align agencies' efforts. Establishing a permanent White House Office of Biotechnology led by a presidentially appointed director would bring the same unified focus to the biotech race.

A White House Office of Biotechnology would help coordinate public- and private-sector efforts and measure America's standing against our competitors. It would also help direct policymakers toward critical priorities -- starting with the investment ecosystem that enables the development of new breakthroughs.

U.S. universities spent a record $68.9 billion on bioscience research in 2024. Yet NIH research funding has fallen steadily since 2023, and venture capital investment has not fully recovered from its post-pandemic decline.

Congress and federal agencies should provide sustained, predictable, and merit-based funding for basic research. Policymakers can also strengthen patent protections and expand incentives for private investment to help small- and mid-size U.S. biotechs, which originate roughly half of new medicines launched worldwide, secure the capital they need to develop promising discoveries.

But scientific discoveries and investment are only the beginning. Promising treatments must also make their way through clinical trials, and America is facing growing competition for that work. A growing share of early development is happening in China, where trials are often faster and less expensive. America's small companies need more cost-effective and efficient options here at home.

The FDA can help by modernizing trial launch requirements, tailoring them to the risks posed by different experimental medicines, and providing clearer guidance and more predictable reviews.

And as more promising medicines move from research and development to production, America must have the capacity to manufacture them at home. U.S. biomanufacturing employment has grown nearly 16% since 2021, demonstrating the growing demand for domestic production.

To help meet that demand, policymakers should establish targeted tax incentives for companies to reshore manufacturing and supply chains and streamline permitting to bring new facilities online faster. They should also invest in training the skilled workers, building the reliable infrastructure, and developing the advanced technologies those facilities will need to work.

These efforts all depend on one another.

The next century of biotechnology leadership is not destined to belong to any nation. It will be earned by the nation with the vision to invest, the courage to innovate, and the resolve to build the future.

John F. Crowley is the President and CEO of the Biotechnology Innovation Organization (BIO). This article originally appeared in STAT.

OpinionStaff Report